Targeting a specific protein in certain lung cancers
Targeting SMARCA2 in SMARCA4-deficient lung cancers in vivo
['FUNDING_R37'] · COLUMBIA UNIVERSITY HEALTH SCIENCES · NIH-11108373
This study is looking at how a protein called SMARCA2 affects lung cancers that don't have another important protein, SMARCA4, and it aims to find new treatments by figuring out if reducing SMARCA2 can help slow down tumor growth for patients with this specific type of lung cancer.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | COLUMBIA UNIVERSITY HEALTH SCIENCES (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11108373 on ClinicalTrials.gov |
What this research studies
This research investigates the role of SMARCA2 in lung cancers that lack the SMARCA4 protein, which is crucial for tumor suppression. By using genetically engineered mouse models, the study aims to understand how degrading SMARCA2 can affect tumor growth and progression in these cancers. The approach involves developing targeted therapies that could selectively inhibit SMARCA2, potentially leading to new treatment options for patients with this specific type of lung cancer. The research seeks to fill a significant gap in effective therapies for patients with SMARCA4-deficient lung adenocarcinomas.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer, specifically those with SMARCA4 alterations.
Not a fit: Patients with lung cancers that do not have SMARCA4 deficiencies or those with other types of lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that improve survival rates and treatment responses for patients with SMARCA4-deficient lung cancers.
How similar studies have performed: While targeting SMARCA2 in this context is a novel approach, previous studies have shown promise in targeting similar pathways in cancer treatment.
Where this research is happening
NEW YORK, UNITED STATES
- COLUMBIA UNIVERSITY HEALTH SCIENCES — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CONCEPCION-CRISOL, CARLA P — COLUMBIA UNIVERSITY HEALTH SCIENCES
- Study coordinator: CONCEPCION-CRISOL, CARLA P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.